Novo Names Galderma Group CFO as New Finance Chief
Galderma Group AG's Chief Financial Officer, Luigi La Corte, has been appointed as the new finance chief at Novo.
Stocks · News reference
Galderma Receives NMPA Approval for Relfydess in China
Galderma has received regulatory approval from China's National Medical Products Administration (NMPA) for Relfydess to treat moderate-to-severe frown lines in adults.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
Galderma Group AG has proposed two new board members and announced that CFO Luigi La Corte will step down to pursue a new opportunity.
Galderma Group AG Files for Acquisition of ZO Skin Health
The German Federal Cartel Office (Bundeskartellamt) has listed a merger control proceeding regarding Galderma Group AG's acquisition of ZO Skin Health.
J.P. Morgan Maintains Overweight Rating on Galderma
J.P. Morgan analysts issued a research note maintaining an overweight rating on Galderma, citing strong growth prospects driven by the Nemluvio drug and the acquisition of ZO Skin Health.
Galderma Launches ALASTIN Restorative Eye Complex with TriHex+ in the U.S.
Galderma has introduced an enhanced version of its ALASTIN Restorative Eye Complex, featuring the proprietary TriHex+ platform to address signs of aging around the eye area.
Berenberg Raises Price Target for Galderma Following Q3 Results
Investment bank Berenberg increased its price target for Galderma Group AG, citing third-quarter financial results that exceeded market expectations.